Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday, sending its Denmark-listed shares up more than 5% as investors bet on the ...

Drug manufacturer Novo Nordisk’s amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like Ozempic ...

Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults ...

Novo Nordisk A/S (NYSE:NVS) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management. Amycretin is developed for subcutaneous and oral ...

Novo Nordisk (NVO) has released full data from a Phase 1b/2a trial for its novel obesity drug, amycretin noting that the injectable, designed to target GLP-1 and amylin receptors, caused up to 24% of ...

"We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of ...